JPWO2023048231A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023048231A5
JPWO2023048231A5 JP2023549745A JP2023549745A JPWO2023048231A5 JP WO2023048231 A5 JPWO2023048231 A5 JP WO2023048231A5 JP 2023549745 A JP2023549745 A JP 2023549745A JP 2023549745 A JP2023549745 A JP 2023549745A JP WO2023048231 A5 JPWO2023048231 A5 JP WO2023048231A5
Authority
JP
Japan
Prior art keywords
cancer
sodium
verteporfin
tumor cells
talaporfin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549745A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023048231A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/035376 external-priority patent/WO2023048231A1/ja
Publication of JPWO2023048231A1 publication Critical patent/JPWO2023048231A1/ja
Publication of JPWO2023048231A5 publication Critical patent/JPWO2023048231A5/ja
Pending legal-status Critical Current

Links

JP2023549745A 2021-09-24 2022-09-22 Pending JPWO2023048231A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021155009 2021-09-24
PCT/JP2022/035376 WO2023048231A1 (ja) 2021-09-24 2022-09-22 腫瘍細胞を死滅させるための医薬

Publications (2)

Publication Number Publication Date
JPWO2023048231A1 JPWO2023048231A1 (https=) 2023-03-30
JPWO2023048231A5 true JPWO2023048231A5 (https=) 2025-05-26

Family

ID=85720780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549745A Pending JPWO2023048231A1 (https=) 2021-09-24 2022-09-22

Country Status (5)

Country Link
US (1) US20250000998A1 (https=)
EP (1) EP4406556A1 (https=)
JP (1) JPWO2023048231A1 (https=)
CN (1) CN117999098A (https=)
WO (1) WO2023048231A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021193928A1 (ja) * 2020-03-27 2021-09-30 株式会社ＰｈｏｔｏＱ３ 腫瘍細胞を死滅させるための医薬

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US20200147233A1 (en) * 2018-10-09 2020-05-14 PhotoQ3 Inc. Method for killing tumor cells and composition used therefor

Similar Documents

Publication Publication Date Title
JP2012502938A5 (https=)
JPWO2023048231A5 (https=)
TW202537643A (zh) 抗體-藥物結合物之用途
Yu et al. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions
MX2025005779A (es) Conjugado de anticuerpo-farmaco, metodo de preparacion y uso del mismo
GEAP202416383A (en) Use of medicament in treatment of tumor disease
Stacchiotti et al. Systemic therapy options for unresectable and metastatic chordomas
Atwell et al. Nuclear epidermal growth factor receptor as a therapeutic target
US20230242554A1 (en) Photosensitizing dye
JPWO2021193928A5 (https=)
Tymon-Rosario et al. Targeted therapies in the treatment of uterine serous carcinoma
JP7329288B2 (ja) 腫瘍細胞を死滅させるための医薬
JP7769386B2 (ja) 腫瘍細胞を死滅させるための医薬
US20250000998A1 (en) Medicament for killing tumor cells
US20200147233A1 (en) Method for killing tumor cells and composition used therefor
JPWO2022170974A5 (https=)
Halani et al. “New targets in non–small-cell lung cancer”—RET, HER2, and KRAS
Hoy Trastuzumab Rezetecan: First Approval
CA3100422A1 (en) Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3
Williams H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich honored with the 2019 Lasker~ DeBakey Clinical Medical Research Award
Schardt et al. HER3-targeted affibodies with optimized formats reduce ovarian cancer progression in a mouse xenograft model
Li et al. 3H-3000, an FGFR2B-specific monoclonal antibody, shows superior tumor killing in vivo
Zhang et al. Novel affibody molecules targeting the AXL extracellular structural domain for molecular imaging and targeted therapy of gastric cancer
TWI920018B (zh) 抗ｈｅｒ３抗體-藥物結合物用於治療ｈｅｒ３突變癌之醫藥的用途
Tudu A prospective comparative study between concurrent chemoradiation with brachytherapy boost with concurrent chemoradiation alone in locally advanced cancer esophagus